IPCA Laboratories Q4 Results 2026: Date, Revenue, PAT & Analyst Outlook

Wed Apr 08 2026

IPCA Laboratories (NSE: IPCA) is preparing to announce its Q4 FY26 financial results for the period ended March 31, 2026. The board of directors is scheduled to meet on May 2026 (Expected) to approve the audited statements and consider a final dividend recommendation. With IPCA Laboratories trading at Rs 1,580 — against a 52-week high of Rs 1,920 and a 1-year return of -8% — the Q4 FY26 results will be a pivotal event for investors.

Analyst estimates for Q4 FY26 revenue stand at Rs 2,200-2,400 Cr, with PAT expectations of Rs 265-300 Cr and margin projections of EBITDA 21-23%. This article covers the IPCA Laboratories Q4 results 2026 date, detailed earnings estimates, five key performance factors, five risks to monitor, analyst ratings and price targets, and answers to the most commonly searched investor questions.

Table of Contents

IPCA Laboratories Q4 Results 2026 Date

Get free investment predictions and live Q4 result alerts on Univest.

IPCA Laboratories has scheduled its Q4 FY26 results for May 2026 (Expected). Here is the broader Q4 FY26 earnings calendar context:

Company	Date	Link
TCS	April 9, 2026	Preview on Univest
Infosys	April 23, 2026	Preview on Univest
IPCA Laboratories	May 2026 (Expected)	This article

Why This Quarter Matters

IPCA Laboratories enters Q4 FY26 with expectations of 8-12% YoY revenue growth. Q4 is the final quarter of the financial year — it determines full-year FY26 performance, sets the FY27 estimate base, and triggers final dividend announcements. At a 1-year return of -8%, this quarter’s results and FY27 guidance will be critical in determining whether the stock can begin a recovery.

IPCA Laboratories Q4 FY26 Earnings Estimates

IPCA Laboratories Q4 FY26 analyst estimates. Source: MOFSL, YES Securities, JM Financial.

Access premium SEBI-registered research on Univest.

Metric	Q3 FY26 Actual	Q4 FY26 Estimate	Driver
Revenue	Rs 2,082 Cr	Rs 2,200-2,400 Cr	Volume + pricing
PAT	Rs 243 Cr	Rs 265-300 Cr	Operating leverage
Margin	EBITDA 21.6%	EBITDA 21-23%	Cost control
Key Growth	–	8-12% YoY revenue growth	Management execution
Dividend	—	Rs 6-9 per share	Board recommendation

Beyond headline numbers, investors will watch for FY27 guidance, margin trajectory, and order/deal pipeline updates. A positive surprise on any two of these parameters could drive a meaningful post-results re-rating.

Screen IPCA Laboratories fundamentals on Univest Screener.

5 Key Factors That Will Drive IPCA Laboratories Q4 FY26 Performance

Revenue Momentum

Analysts expect Rs 2,200-2,400 Cr in revenue for Q4 FY26 (Q3: Rs 2,082 Cr). Management’s ability to translate the order pipeline into recognised revenue will be the first test. Q4 is seasonally important for the Pharma sector, driven by year-end order execution and government capex push.

Margin Trajectory

Q4 FY26 margin expectations are EBITDA 21-23%, compared to EBITDA 21.6% in Q3. Input cost trends, employee expenses, and pricing power will determine the outcome. Any margin beat would be a significant positive catalyst given sector-wide cost pressure.

PAT Quality

Net profit is estimated at Rs 265-300 Cr. Investors will assess whether PAT is driven by operational improvement or one-time items. A clean recurring profit print is more positively received than one inflated by non-operational gains.

Management Guidance for FY27

The most consequential output from the Q4 FY26 announcement will be FY27 guidance — revenue growth bands, margin targets, capex plans, and macro risk commentary. Credible and specific guidance for FY27 will be valued highly by institutional investors.

Dividend Declaration

IPCA Laboratories is expected to consider a final dividend of Rs 6-9 per share at the board meeting. The quantum signals confidence in free cash flow generation and sets expectations for FY27 capital allocation strategy.

5 Risks to Watch in IPCA Laboratories Q4 FY26

US Tariff and Macro Headwinds

The 26% US reciprocal tariff on Indian goods has created macro uncertainty affecting all Indian equities. For IPCA Laboratories, indirect impacts include FII outflows and earnings estimate cuts if global demand slows. Tariff negotiation progress between India and the US remains the key macro wildcard.

Earnings Miss Risk

If IPCA Laboratories’s Q4 FY26 results miss estimates, the stock could correct sharply — regardless of the longer-term fundamental story. Investors should monitor revenue versus the Rs 2,200-2,400 Cr estimate and PAT versus Rs 265-300 Cr as the two primary watchpoints on results day.

FY27 Guidance Below Consensus

If management’s FY27 guidance for revenue or margins falls below Street expectations, the stock may decline even if Q4 numbers are in line. In the current macro environment, forward guidance carries more weight than the reported quarter.

FII Outflow Continuation

FIIs sold Rs 22,000 crore in Indian equities in one week following the tariff announcement. Continued selling pressure would create headwinds for IPCA Laboratories regardless of company-specific fundamentals.

Regulatory Risk

The Pharma sector operates within evolving regulatory frameworks. Any policy changes that increase compliance costs or alter competitive dynamics could affect IPCA Laboratories’s profitability beyond current consensus models.

IPCA Laboratories Share Price and Analyst Ratings

IPCA Laboratories is trading at Rs 1,580 as of early April 2026, against a 52-week high of Rs 1,920 and 52-week low of Rs 1,340. Market cap stands at Rs 20,100 Cr. The 1-year return of -8% reflects sector headwinds alongside company-specific factors.

Brokerage	Rating	Target Price	Thesis
MOFSL	Buy	Rs 1,900	API + branded formulations; EU
YES Securities	Buy	Rs 1,850	Anti-malarial and pain therapy
JM Financial	Add	Rs 1,800	UNICEF tenders + Europe
Emkay	Buy	Rs 1,820	Margin as US business recovers

Download the Univest iOS App or Univest Android App to track IPCA Laboratories’s live price and receive real-time Q4 result alerts.

Conclusion

IPCA Laboratories Q4 FY26 results on May 2026 (Expected) will be a key event for investors monitoring the Pharma sector. Analysts project PAT of Rs 265-300 Cr and revenue of Rs 2,200-2,400 Cr. At a CMP of Rs 1,580 with analyst targets ranging from Rs 1,820 to Rs 1,900, the stock offers risk-reward for informed investors. FY27 guidance will be the most critical post-results catalyst.

For more Q4 FY26 previews across sectors, visit Univest Blogs.

Frequently Asked Questions

What is the IPCA Laboratories Q4 results 2026 date?

The IPCA Laboratories Q4 results 2026 date is May 2026 (Expected). The board of directors will meet to approve the audited Q4 FY26 financial results and consider a dividend recommendation for FY26.

What is the IPCA Laboratories Q4 FY26 PAT estimate?

Analysts estimate IPCA Laboratories Q4 FY26 PAT in the range of Rs 265-300 Cr, based on revenue of Rs 2,200-2,400 Cr and margin of EBITDA 21-23%. Actual results may differ from consensus estimates.

What is IPCA Laboratories’s share price ahead of Q4 results?

IPCA Laboratories is trading at Rs 1,580 as of early April 2026. The 52-week high is Rs 1,920 and the 52-week low is Rs 1,340. The 1-year return is -8% and market cap is Rs 20,100 Cr.

Will IPCA Laboratories declare a dividend in Q4 FY26?

IPCA Laboratories is expected to consider a final dividend of Rs 6-9 per share at the Q4 FY26 board meeting on May 2026 (Expected), subject to board approval and AGM ratification.

Which analysts have a Buy rating on IPCA Laboratories?

MOFSL (Buy, Rs 1,900), YES Securities (Buy, Rs 1,850), JM Financial (Add, Rs 1,800), Emkay (Buy, Rs 1,820) have positive ratings on IPCA Laboratories heading into Q4 FY26.

What were IPCA Laboratories Q3 FY26 results?

IPCA Laboratories reported Q3 FY26 revenue of Rs 2,082 Cr and PAT of Rs 243 Cr, with margin at EBITDA 21.6%. These form the baseline against which Q4 FY26 estimates are benchmarked.

When do Infosys and TCS announce Q4 results 2026?

TCS declared Q4 FY26 results on April 9, 2026. Read the TCS Q4 Results 2026 preview on Univest Blogs. Infosys Q4 FY26 results are scheduled for April 23, 2026. Read the Infosys Q4 Results 2026 preview on Univest Blogs.

Is IPCA Laboratories a good investment ahead of Q4 results?

This depends on your risk appetite, investment horizon, and portfolio context. IPCA Laboratories has compelling long-term factors alongside genuine near-term risks. Consult a SEBI-registered financial advisor before making any investment decision. Use the Univest Screener to assess fundamentals independently.

Disclaimer: Investment in the share market is subject to risk. This article is for informational and educational purposes only and does not constitute investment advice. All financial data and analyst estimates are sourced from publicly available information including NSE/BSE filings. Verify all numbers before investing. Consult a SEBI-registered advisor before making investment decisions.